respiratory problems in premature infants
DESCRIPTION
Respiratory problems in premature infants. Dr. Rozin Ilya Department of Neonatology Kaplan Medical Center. Respiratory problems. Respiratory Distress Syndrome (RDS) or Hyaline Membrane Diseases (HMD) Broncho-Pulmonary Dysplasia (BPD). Respiratory Distress Syndrome. Definition. - PowerPoint PPT PresentationTRANSCRIPT
Respiratory problems in premature infants
Dr. Rozin IlyaDepartment of Neonatology Kaplan Medical Center
Respiratory problems
• Respiratory Distress Syndrome (RDS) or Hyaline Membrane Diseases (HMD)
• Broncho-Pulmonary Dysplasia (BPD)
Respiratory Distress Syndrome
Definition
• Also known as hyaline membrane disease
• Deficiency of pulmonary surfactant in an immature lung
• Common respiratory disorder of premature infants
• RDS can also be due to genetic problems with lung development
Epidemiology
• Major cause of morbidity and mortality in preterm infants• 20,000-30,000 newborn infants
each year ( in US)• Incidence and severity of RDS are
related inversely to gestational age of newborn infant (most case before 37 weeks)• 26-28 weeks gestation : 50% • 30-31 weeks gestation : <30%
Epidemiology
• Overall incidence in 501-1500 grams: 42%
• 501-750 grams: 71%• 751-1000 grams: 54%• 1001-1250 grams: 36%• 1251-1500 grams: 22%
Other risk factors for RDS
Increased Risk• Prematurity• Male gender• Familial predisposition• Cesarean section without
labor• Perinatal asphyxia• Caucasian race• Infant of diabetic mother• Chorioamnionitis• Non-Immune hydrops
fetalis• Multiple pregnancy (twins
or more)
Decreased Risk• Chronic intra-uterine stress• Prolonged rupture of
membranes• Maternal hypertension or
toxemia• IUGR/SGA• Antenatal glucocorticoids• Maternal use of
narcotics/cocaine• Tocolytic agents• Hemolytic disease of the
newborn
Phases of Lung Development
Lung Development
Surfactant
• Complex lipoprotein • Composed of 6
phospholipids and 4 apoproteins
• Surfactant contains• 70-80%
phospholipids, • 8-10% protein, and• 10% neutral lipids
Surfactant Metabolism
Surfactant Metabolism
4 surfactant apoproteins
• Surfactant protein B (SP-B)• Surfactant protein C (SP-C) for preventing atelectasis, and
• Surfactant protein A (SP-A) - facilitates phagocytosis of pathogens by macrophages and their clearance from the airways
• Surfactant protein D (SP-D) – if absent -increased surfactant lipid pools in the airspaces and emphysema in mice
Assessment of Fetal Lung Maturity
• Lecithin / sphingomyelin (L/S) ratio
• Lamellar body counts
• Phosphatidylglycerol• After 35 weeks gestation
L/S Ratio
Pathophysiology
Etiology
• Preterm delivery• Mutations in genes encoding surfactant
proteins • SP-B• SP-C• ATP-binding cassette (ABC) transporter
A3 (ABCA3) - is critical for proper formation of lamellar bodies and surfactant function and may also be important for lung function in other pulmonary diseases
Lung Compliance
Hyaline Membranes
Surfactant Inactivation
• Meconium and blood can inactivate surfactant activity (Full-term > Preterm)
• Proteinaceous edema and inflammatory products increase conversion rate of surfactant into its inactive vesicular form• Oxidant and mechanical stress associated with
mechanical ventilation that uses large TV
Clinical Manifestations
• Tachypnea• Nasal flaring• Grunting• Intercostal, sub xiphoid, and
subcostal retractions • Cyanosis • Apnea
Differential Diagnosis
• TTN• MAS• Pneumonia• Cyanotic Congenital Heart Disease• Pneumomediastinum, pneumothorax• Hypoglycemia• Metabolic problems• Hematologic problems
• Anemia, polycythemia• Congenital anomalies of the lungs
Diagnosis
• Onset of progressive respiratory failure shortly after birth
• Characteristic chest radiograph• Laboratory tests – rule out infection • Analysis of blood gas:
• Hypoxia• Hypercarbia
Chest X Ray
“ground glass”
Prevention
• Antenatal glucocorticoids• Enhances maturational changes in lung
architecture and inducing enzymes • Stimulate phospholipid synthesis and
release of surfactant• All pregnant mothers at risk for preterm
delivery between 24 and 34 weeks gestation should receive ACS
Treatment
• Surfactant Therapy• Assisted Ventilation Techniques and Oxygen
therapy (be careful) • Supportive Care
• Thermoregulation• Fluid Management• Nutrition• Antibiotic therapy• Gentle handling
Prognosis
Acute complications of respiratory distress syndrome : • Alveolar rupture• Infection• Intracranial hemorrhage and periventricular leukomalacia• Patent Ductus Arteriosus (PDA) with increasing left-to-right
shunt• Pulmonary hemorrhage• Necrotizing enterocolitis (NEC) and/or gastrointestinal (GI)
perforation• Apnea of prematurity
Prognosis
• Chronic complications of respiratory distress syndrome :
• Broncho pulmonary dysplasia (BPD)
• Retinopathy of prematurity (ROP)
• Neurologic impairment
Bronchopulmonary dysplasia
• Bronchopulmonary dysplasia (BPD) is a form of chronic lung disease that develops in preterm neonates treated with oxygen and positive-pressure ventilation (PPV).
• The pathogenesis of this condition remains complex and poorly understood.
Pathogenesis
Definition
• 1967, Northway et al. : premature infants with RDS, resaved prolonged ventilation, with high concentration of oxygen and high peak inspiratory pressure
• All require oxygen at 28 days after birth and progressive change on chest x-ray
Definition
• 1979, Bancalari: same to Northway + tachypnea and crackles or retraction.
• 1988, new criterion: oxygen supplementation at 36 weeks postmenstrual age (PMA)
• - more accurately predicted abnormal pulmonary outcome at 2 years of age
• - with medical care more infant with oxygen at 28 days
Definition
2000 ,National Institute of Child Health and Human Development (NICHD)
Definition
• Because of absent specified in the consensus BPD definition, it was recommended that a physiologic test confirming the need for supplementation oxygen be performed
Epidemiology
• Incidence:• 42-46% (BW-501-750g)• 25-33% (BW=751-
1000g)• 11-14%
(BW=1001=1250g)• 5-6% (BW=1251-1500g)
• Risk factors:• Prematurity, low BW• White boys• Genetic heritability
Epidemiology
• By the NICHD at 2010 from Neonatal Research Network
• BW 401-1500 gr• GA 22 0/7 – 28 6/7 weeks• BPD of all diagnosis - 68%• Mild - 27%• Moderate – 23%• Severe – 18%
Pathology
• “Old” BPD: Airway inflammation Fibrosis Smooth muscle hypertrophy
• “New” BPD: Lung development arrests before alveolarization:
lung have larger but fewer alveoli than normal lung
Pulmonary vasculature to be dysmorphic
Pathology
• “Old BPD” (before surfactant and steroids)• Cystic changes,
heterogeneous aeration
• “New BPD” (after surfactant and steroids)• More uniform inflation and
less fibrosis, absence of small and large airway epithelial metaplasia and smooth muscle hypertrophy
• Some parenchymal opacities, but more homogenous aeration and less cystic areas
• PATHOLOGIC HALLMARKS: larger simplified alveoli and dysmorphic pulmonary vasculature
Pathology
• Old BPD: • Airway injury,
inflammation and parenchymal fibrosis due to mechanical ventilation and oxygen toxicity
• New BPD:• Decreased septation and
alveolar hypoplasia leading to fewer and larger alveoli, so less surface area for gas exchange
• Dysregulation of vascular development leading to abnormal distribution of alveolar capillaries and thickened muscular layer of pulmonary arterioles
Pathogenesis
Pathogenesis
• Chorioamnionitis – caused by an ascending infection, as possible cause
• But histologic chorioamnionitis to be protective ( same umbilical vasculitis) – potential role of transcription factor nuclear factor kB and inflammation
• Ureaplasma colonization • Bacterial sepsis
Pathogenesis
• Hemodynamic significantly PDA and surgery ligation
• Mechanical ventilation (volutrauma and barotrauma)
• Oxygen toxicity• High volume of fluids intake n the first few
days after birth• Lower serum cortisol level (in VLBW) – early
adrenal insufficiency
Outcomes
• Higher rate recurrent hospitalization in the first year after birth
• Lung disease in adulthood: airway obstruction, reactive airways, emphysema
• Affect growth• Cardiovascular sequelae: pulmonary artery
hypertension, cor pulmonale, systemic hypertension
• Poor neurodevelopmental outcomes: language delay, increased fine and gross motor impairment
Prevention and therapy
• Antenatal: corticosteroids administration• standard of care – 24 – 34 weeks• effect on the incidence of BPD controversial• in animals studies – arrest
alveolarization and microvascular development
Prevention and therapy
• Postnatal: postnatal corticosteroids therapy • decreased time to extubation• early use – poor
neurodevelopmental outcomes (CP)• adverse effects: hyperglycemia,
hypertension, GI bleeding, hypertrophic cardiomyopathy, infection
Prevention and therapy
Azithromycin• macrolides antibiotic• anti-inflammatory effect • active against Ureaplasma infection• in a RCT no statistic significance (for
6 weeks of therapy)
Prevention and therapy
Vitamin A:• regulation of lung development • injury repair • low level – increased risk to BPDVitamin E and Selenium:• study result have been mixed• selenium works synergistically with Vit E
to prevent peroxide formation – not show to
reduce risk to BPD
Prevention and therapy
Caffeine: • significant reduce in BPDPentoxiphilline:• non specific phosphodiesterase inhibitor • decreased pulmonary inflammation Cromolyn:• mast cell stabilizer
• non protective effect
Prevention and therapy
Nitric Oxide:• benefit on oxidative stress and lung
development – in animal studies• not support the use in routine careSurfactant:• not decreased incidence of BPD• improving respiratory care • prophylactic therapy is associated with
lower risk of BPD
Prevention and therapy
Ventilatory strategies:• permissive hypercapnia (pH>7.20 and
pCO2 from 45 to 55 mmHg)• gentle ventilation ( SIMV, HFV, Volume-
targeted ventilation, NSIMV (NIPPV) or NCPAP)• INSURE used • adequate oxygenation – difficult
Prevention and therapy
Nutrition:• excessive fluids intake – more risk
for BPD• if BPD – infant may need up to 20%-
40% more kilocalories
Prevention and therapy
• Therapy of established BPD:
Inhaled steroids:• evidence supporting is mixt• RCT for early therapy – no support Diuretics:• for decreased pulmonary alveolar and interstitial edema• routine used loop diuretics not recommended• Thiazide + Spironolactone Bronchodilators:• most commonly β adrenergic agonist• short term improvement • for acute exacerbation care only
Thank you